Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma

NCT06923475 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Extrahepatic Cholangiocarcinoma
Perihilar Cholangiocarcinoma
Distal Cholangiocarcinoma
Resectable
Borderline Resectable

Interventions

DRUG: Pembrolizumab
DRUG: Gemcitabine, Cisplatin

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]